Clinical Drug Investigation

, Volume 27, Issue 12, pp 827–832 | Cite as

Topical Application of Dexamethasone to Prevent Cerebral Vasospasm after Aneurysmal Subarachnoid Haemorrhage

A Pilot Study
Original Research Article

Abstract

Background and objective: Cerebral vasospasm is a common and serious complication of aneurysmal subarachnoid haemorrhage (SAH). Many studies have revealed a role of inflammation in the development of cerebral vasospasm. This study aimed to investigate whether topically administered dexamethasone could attenuate vasospasm in SAH patients.

Methods: Paired samples were designed to compare postoperative mean middle cerebral artery velocity between treated patients and controls matched for age (+10 years), sex, location and size (small, medium or large) of aneurysm, as well as baseline mean middle cerebral artery velocity. We enrolled ten consecutive aneurysmal SAH patients who had Hunt-Hess (HH) grade 3 and Fish grade 3 lesions and were admitted within 24 hours following the onset of SAH. These patients were treated with dexamethasone 10mg topically at the end of the operation. Each treated patient was matched with a control patient who did not receive topical dexamethasone. All controls also had HH grade 3 and Fish grade 3 SAH and were admitted within 24 hours after the onset of SAH. Serial measurements of mean middle cerebral artery velocity were performed postoperatively every day for 2 weeks. Results were analysed with the paired t-test.

Results: One patient (10%) in the treated group had vasospasm, without neurological deficit, compared with four patients (40%) in the control group, one of whom had hemiplegia. Paired t-test showed that the mean middle cerebral artery velocity in controls was significantly higher than that in treated patients on days 4-14.

Conclusion: Topical application of dexamethasone is a promising strategy for prevention and attenuation of vasospasm following aneurysmal SAH.

Keywords

Dexamethasone Nimodipine Papaverine Cerebral Vasospasm Epidermoid Cyst 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurg 2006; 59: 21–7CrossRefGoogle Scholar
  2. 2.
    Pasqualin A. Epidemiology and pathophysiology of cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg Sci 1998;42: 15–21PubMedGoogle Scholar
  3. 3.
    Nagata K, Sasaki T, Mori T, et al. Cisternal talc injection in dog can induce delayed and prolonged arterial constriction resembling cerebral vasospasm morphologically and pharmacologically. Surg Neurol 1996 May; 45(5): 442–7PubMedCrossRefGoogle Scholar
  4. 4.
    Hirashima Y, Endo S, Otsuji T, et al. Platelet-activating factor and cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 1993 Apr; 78(4): 592–7PubMedCrossRefGoogle Scholar
  5. 5.
    Hirashima Y, Endo S, Ohmori T, et al. Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cere- brospinal fluid of patients with subarachnoid hemorrhage. J Neurosurg 1994 Jan; 80(1): 31–6PubMedCrossRefGoogle Scholar
  6. 6.
    Abe Y, Kasuya H, Suzuki S, et al. Effect of a platelet-activating factor antagonist, E5880, on cerebrovasospasm following subarachnoid hemorrhage in a canine double-hemorrhage model. Eur J Pharmacol 2002 Nov 29; 455(2-3): 127–33PubMedCrossRefGoogle Scholar
  7. 7.
    Hirashima Y, Endo S, Kato R, et al. Prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by the platelet-activating factor antagonist, E5880. J Neurosurg 1996 May; 84(5): 826–30PubMedCrossRefGoogle Scholar
  8. 8.
    Hirashima Y, Nakamura S, Endo S, et al. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res 1997 Oct; 22(10): 1249–55PubMedCrossRefGoogle Scholar
  9. 9.
    Bowman G, Dixit S, Bonneau RH, et al. Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery 2004 Mar; 54(3): 719–25; discussion 25-6PubMedCrossRefGoogle Scholar
  10. 10.
    Bowman G, Bonneau RH, Chinchilli VM, et al. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocrit Care 2006; 5(3): 222–9PubMedCrossRefGoogle Scholar
  11. 11.
    Satoh M, Date I, Nakajima M, et al. Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits. Stroke 2001 Jan; 32(1): 225–31PubMedCrossRefGoogle Scholar
  12. 12.
    Recinos PF, Pradilla G, Thai QA, et al. Controlled release of lipopolysaccharide in the subarachnoid space of rabbits induces chronic vasospasm in the absence of blood. Surg Neurol 2006 Nov; 66(5): 463–9; discussion 9PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou ML, Shi JX, Hang CH, et al. Potential contribution of nuclear factor-kappaB to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. J Cereb Blood Flow Metab. In pressGoogle Scholar
  14. 14.
    Asaeda M, Sakamoto M, Kurosaki M, et al. A non-enzymatic derived arachidonyl peroxide, 8-iso-prostaglandin F2 alpha, in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage participates in the pathogenesis of delayed cerebral vasospasm. Neurosci Lett 2005 Jan 20; 373(3): 222–5PubMedCrossRefGoogle Scholar
  15. 15.
    Sasaki T, Kasuya H, Onda H, et al. Role of p38 mitogen-activated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke 2004 Jun; 35(6): 1466–70PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang Z, Nagata I, Kikuchi H, et al. Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke 2001 Jul; 32(7): 1665–72PubMedCrossRefGoogle Scholar
  17. 17.
    Nakamura S, Tsubokawa T, Yoshida K, et al. Appearance of collagen fibers in the cerebral vascular wall following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1992 Nov; 32(12): 877–82CrossRefGoogle Scholar
  18. 18.
    Macdonald RL, Zhang ZD, Ono S, et al. Up-regulation of parathyroid hormone receptor in cerebral arteries after subarachnoid hemorrhage in monkeys. Neurosurgery 2002 May; 50(5): 1083–91; discussion 91-3PubMedGoogle Scholar
  19. 19.
    Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000 Dec; 31(12): 2971–5PubMedCrossRefGoogle Scholar
  20. 20.
    Aihara Y, Kasuya H, Onda H, et al. Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage. Stroke 2001 Jan; 32(1): 212–7PubMedCrossRefGoogle Scholar
  21. 21.
    Onda H, Kasuya H, Takakura K, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999 Nov; 19(11): 1279–88PubMedCrossRefGoogle Scholar
  22. 22.
    Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003 Aug; 99(2): 376–82PubMedCrossRefGoogle Scholar
  23. 23.
    Yatsushige H, Yamaguchi M, Zhou C, et al. Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke 2005 Jul; 36(7): 1538–43PubMedCrossRefGoogle Scholar
  24. 24.
    Chyatte D. Prevention of chronic cerebral vasospasm in dogs with ibuprofen and high-dose methylprednisolone. Stroke 1989 Aug; 20(8): 1021–6PubMedCrossRefGoogle Scholar
  25. 25.
    Pradilla G, Thai QA, Legnani FG, et al. Local delivery of ibuprofen via controlled-release polymers prevents angiographic vasospasm in a monkey model of subarachnoid hemorrhage. Neurosurgery 2005 Jul; 57(1 Suppl): 184–90; discussion 90PubMedCrossRefGoogle Scholar
  26. 26.
    Thai QA, Oshiro EM, Tamargo RJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke 1999 Jan; 30(1): 140–7PubMedCrossRefGoogle Scholar
  27. 27.
    Chyatte D, Rusch N, Sundt Jr TM. Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. J Neurosurg 1983 Dec; 59(6): 925–32PubMedCrossRefGoogle Scholar
  28. 28.
    Chyatte D, Fode NC, Nichols DA, et al. Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1987 Aug; 21(2): 157–60PubMedCrossRefGoogle Scholar
  29. 29.
    Chyatte D, Sundt Jr TM. Response of chronic experimental cerebral vasospasm to methylprednisolone and dexamethasone. J Neurosurg 1984 May; 60(5): 923–6PubMedCrossRefGoogle Scholar
  30. 30.
    Kim CJ, Bassiouny M, Macdonald RL, et al. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Stroke 1996 Sep; 27(9): 1629–33PubMedCrossRefGoogle Scholar
  31. 31.
    Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 1998 Sep; 29(9): 1930–5; discussion 5-6PubMedCrossRefGoogle Scholar
  32. 32.
    Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 2001 Jul; 95(1): 44–50PubMedCrossRefGoogle Scholar
  33. 33.
    Auer LM, Ito Z, Suzuki A, et al. Prevention of symptomatic vasospasm by topically applied nimodipine. Acta Neurochir (Wien) 1982; 63(1-4): 297–302CrossRefGoogle Scholar
  34. 34.
    Welty TE. Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage. Clin Pharm 1987 Dec; 6(12): 940–6PubMedGoogle Scholar
  35. 35.
    Schurkamper M, Medele R, Zausinger S, et al. Dexamethasone in the treatment of subarachnoid hemorrhage revisited: a comparative analysis of the effect of the total dose on complications and outcome. J Clin Neurosci 2004 Jan; 11(1): 20–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of NeurosurgeryBeijing Tian Tan Hospital, Capital Medical UniversityBeijingChina

Personalised recommendations